Halberd Corporation (HALB)
USD 0.0
(4.76%)
USD 0.0
(4.76%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 150 Thousand USD | 0.0% |
| 2023 | 150 Thousand USD | 0.0% |
| 2022 | 150 Thousand USD | 0.0% |
| 2021 | 150 Thousand USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2017 | 460.44 Thousand USD | -32.71% |
| 2016 | 684.24 Thousand USD | 0.0% |
| 2008 | 310.9 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 150 Thousand USD | 0.0% |
| 2024 Q4 | 150 Thousand USD | 0.0% |
| 2024 Q3 | 150 Thousand USD | 0.0% |
| 2024 Q2 | 150 Thousand USD | 0.0% |
| 2023 Q4 | 150 Thousand USD | 0.0% |
| 2023 Q2 | 150 Thousand USD | 0.0% |
| 2023 Q1 | 150 Thousand USD | 0.0% |
| 2023 FY | 150 Thousand USD | 0.0% |
| 2023 Q3 | 150 Thousand USD | 0.0% |
| 2022 Q4 | 150 Thousand USD | 0.0% |
| 2022 Q3 | 150 Thousand USD | 0.0% |
| 2022 Q2 | 150 Thousand USD | 10.63% |
| 2022 Q1 | 135.58 Thousand USD | -9.61% |
| 2022 FY | 150 Thousand USD | 0.0% |
| 2021 Q4 | 150 Thousand USD | 9.49% |
| 2021 FY | 150 Thousand USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q3 | 137 Thousand USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2017 FY | 460.44 Thousand USD | -32.71% |
| 2016 FY | 684.24 Thousand USD | 0.0% |
| 2009 Q2 | 28.32 Thousand USD | -91.39% |
| 2009 Q3 | 84.02 Thousand USD | 196.63% |
| 2009 Q1 | 328.9 Thousand USD | 5.79% |
| 2008 FY | 310.9 Thousand USD | 0.0% |
| 2008 Q4 | 310.9 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.654% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 76.193% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.671% |
| Adynxx, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -22.449% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 57.368% |
| Rebus Holdings, Inc. | 310 Thousand USD | 51.613% |
| Skye Bioscience, Inc. | 4.61 Million USD | 96.75% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.496% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -483.226% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 97.445% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.636% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 96.361% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 62.673% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.454% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 93.551% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 84.182% |
| Mesoblast Limited | 118.7 Million USD | 99.874% |
| Marizyme, Inc. | 18.71 Million USD | 99.199% |
| Genus plc | 233.1 Million USD | 99.936% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 94.881% |
| Pharming Group N.V. | 171.54 Million USD | 99.913% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 83.109% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 88.836% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 80.0% |
| ContraFect Corporation | 2.88 Million USD | 94.793% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -10.712% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 89.629% |
| IMV Inc. | 28.88 Million USD | 99.481% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 97.349% |
| MultiCell Technologies, Inc. | 202.58 USD | -73944.822% |
| ONE Bio Corp. | 19.71 Million USD | 99.239% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.739% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | 89.965% |
| Q BioMed Inc. | 4.1 Million USD | 96.35% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.547% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 87.789% |
| Biomind Labs Inc. | 735.54 Thousand USD | 79.607% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.778% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 95.043% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.846% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 58.3% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -5.994% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 93.358% |
| GB Sciences, Inc. | 1.75 Million USD | 91.474% |
| Alpha Cognition Inc. | 1.22 Million USD | 87.709% |
| HST Global, Inc. | 98.31 Thousand USD | -52.565% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 39.691% |
| Enzolytics Inc. | 996.33 Thousand USD | 84.945% |
| Agentix Corp. | 50 Thousand USD | -200.0% |
| Resverlogix Corp. | 6.49 Million USD | 97.689% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 41.313% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 99.25% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 97.879% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 94.462% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1366.993% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.964% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 25.23% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 93.744% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 34.581% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -0.905% |
| Kadimastem Ltd | 891.22 Thousand USD | 83.169% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.262% |
| BioStem Technologies, Inc. | 4.71 Million USD | 96.816% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 40.044% |
| LadRx Corporation | 33.6 Thousand USD | -346.349% |
| Cell Source, Inc. | 9.25 Million USD | 98.379% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 80.164% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 80.164% |
| NovAccess Global Inc. | 2.19 Million USD | 93.181% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | 34.319% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 28.902% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 96.99% |
| Mobile Lads Corp. | 484.28 Thousand USD | 69.026% |
| CytoDyn Inc. | 30.07 Million USD | 99.501% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 98.082% |
| SYBLEU INC | 477.5 Thousand USD | 68.586% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 96.832% |
| International Stem Cell Corporation | 4.17 Million USD | 96.41% |
| Bioxytran, Inc. | 1.92 Million USD | 92.208% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -140.335% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 93.122% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 98.196% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 98.253% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 90.357% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 44.03% |
| Neutra Corp. | 54.15 Thousand USD | -176.978% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 91.803% |
| PureTech Health plc | 25.51 Million USD | 99.412% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 87.747% |
| IXICO plc | 472.02 Thousand USD | 68.222% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 99.032% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.759% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Cellectis S.A. | 92.77 Million USD | 99.838% |